CLINICAL TRIALS PROFILE FOR VARICELLA VIRUS VACCINE LIVE

All Clinical Trials for varicella virus vaccine live

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00641446 ↗	Varicella Vaccination With Pulmicort	Completed	AstraZeneca	Phase 4	2001-10-01	A study to determine whether treatment with Pulmicort in children has any effect on the varicella vaccine
NCT01356004 ↗	Effective Study of Live Attenuated Varicella Vaccine to Treat Severe Resistant Psoriasis	Completed	Cairo University	Phase 4	2010-01-01	Immunotherapy was reported in the treatment of psoriasis. Treatment of resistant psoriasis may be difficult and cyclosporine can induce some remission. The investigators hypothesized that the combined use of live attenuated varicella vaccine as an adjuvant therapy to low dose cyclosporine in the treatment of severe resistant psoriasis can give positive responses.
NCT01474720 ↗	Zostavax in Systemic Lupus Erythematosus	Completed	Oklahoma Medical Research Foundation	Phase 1	2011-11-01	Individuals with systemic lupus erythematosus (SLE, lupus) appear to be at increased risk for the development of shingles, a painful reactivation of the varicella zoster virus that causes chicken pox. The investigators propose to study the immune response to commercially available Zostavax vaccine (shingles vaccine) in adult patients with SLE who have minimal disease activity and are on mild immunosuppressant medications, and to compare the immune response to that seen in healthy people following vaccination. Acceptable immunosuppressive drugs permitted in the study are those felt to be safe according to Centers for Disease Control guidelines. Ten healthy people and 10 SLE patients (all over 50 years of age) will be recruited to receive a single, standard dose of Zostavax. Blood samples and physical examination will be performed prior to injection, then 2,6,and 12 weeks following vaccination. All participants will receive active vaccine, there is no placebo group.
NCT01506661 ↗	Safety of Zostavax Vaccination in Rheumatoid Arthritis	Completed	Oklahoma Medical Research Foundation	Phase 1	2012-01-01	Herpes Zoster (shingles) is caused by reactivation of latent varicella zoster virus (VZV) that usually occurs decades following initial exposure. The risk of developing shingles increases with age. Shingles presents as a painful, itchy blistering rash that usually involves a single portion of the skin and lasts about 7-10 days. The risk of developing shingles increases with age in healthy people, and has been shown in some studies to be increased in people with rheumatoid arthritis and other autoimmune diseases. Zostavax, a live-attenuated vaccine against the varicella zoster virus, was first approved by the FDA for the prevention of Shingles among people 60 years and older, and is now approved for use in people aged 50 years and older. Because rheumatoid arthritis and some of the medications used to treat rheumatoid arthritis can impair the body's immune system, it is not known how much of an immune response can be generated in people with rheumatoid arthritis. The goals of this study are to measure the immune response after standard vaccination with Zostavax in people with rheumatoid arthritis in comparison to people with healthy immune systems. All participants will be 50 years old or older, and subjects with rheumatoid arthritis will not be eligible if they are taking certain biologic medications, including TNF inhibitors (Etanercept or Adalimumab). Ten healthy subjects and 10 subjects with rheumatoid arthritis will all receive a single vaccination with Zostavax, then will be followed for 12 weeks to assess the immune response and for the development of local rash or other potential side effects.

Clinical Trial Conditions for varicella virus vaccine live

Condition Name

Condition Name for varicella virus vaccine live
Intervention	Trials
Psoriasis	4
Psoriatic Arthritis	3
Rheumatoid Arthritis	3
Ankylosing Spondylitis	2

Condition MeSH

Condition MeSH for varicella virus vaccine live
Intervention	Trials
Herpes Zoster	6
Arthritis	4
Psoriasis	4
Chickenpox	4

Clinical Trial Locations for varicella virus vaccine live

Trials by Country

Trials by Country for varicella virus vaccine live
Location	Trials
United States	87
Canada	2
Puerto Rico	1
Sweden	1
Korea, Republic of	1

Trials by US State

Trials by US State for varicella virus vaccine live
Location	Trials
New York	5
California	4
Texas	4
Pennsylvania	3
Oregon	3

Clinical Trial Progress for varicella virus vaccine live

Clinical Trial Phase

Clinical Trial Phase for varicella virus vaccine live
Clinical Trial Phase	Trials
PHASE4	1
PHASE1	1
Phase 4	5

Clinical Trial Status

Clinical Trial Status for varicella virus vaccine live
Clinical Trial Phase	Trials
Completed	8
Active, not recruiting	3
Not yet recruiting	2

Clinical Trial Sponsors for varicella virus vaccine live

Sponsor Name

Sponsor Name for varicella virus vaccine live
Sponsor	Trials
University of Alabama at Birmingham	2
Oklahoma Medical Research Foundation	2
Merck Sharp & Dohme Corp.	2

Sponsor Type

Sponsor Type for varicella virus vaccine live
Sponsor	Trials
Other	17
Industry	8
NIH	3

Varicella virus vaccine live Market Analysis and Financial Projection

Last updated: February 6, 2026

What Are the Recent Developments in Clinical Trials for the Varicella Virus Vaccine Live?

Recent clinical trials for the live attenuated varicella vaccine, such as those associated with the licensed product Varivax (Merck) and other developmental candidates, focus on safety, immunogenicity, and efficacy across different age groups and populations. As of Q4 2022, clinical trial registries, such as ClinicalTrials.gov, list over a dozen ongoing or recently completed studies.

Clinical Trial Status and Focus

• Phase II/III Trials: Most ongoing trials evaluate efficacy in children aged 12 months to 12 years. These include comparison with existing vaccines and dosage optimizations.
• Vaccine Optimization: Trials assess varying viral titers and vaccination schedules to optimize immune response while minimizing adverse effects.
• Special Populations: Subpopulations like immunocompromised children, adults, and pregnant women feature in exploratory studies to expand indications.
• New Formulations: The development of combination vaccines and alternative delivery methods (e.g., nasal) remains an active research area.

Key Trials and Results

• Immunogenicity: Trials report seroconversion rates exceeding 99% in children after one or two doses, aligned with existing vaccines.
• Safety Profile: Asthma exacerbation, fever, and mild rash emerge as most common adverse events, consistent with existing live vaccines.
• Efficacy: Protective efficacy is reported at 85-95%, comparable with licensed products, with some early studies showing promising results for reduced adverse reactions.

What Is the Current Market Landscape for Live Attenuated Varicella Vaccines?

Established Market Participants

The main commercially available varicella vaccine, Varivax (Merck & Co.), holds approximately 90% of the global market share, supported by its long-standing approval and extensive usage data. Other players include GlaxoSmithKline (Varilrix), which has a smaller footprint.

Market Size and Trends

• Global Market Value: Estimated at USD 2.3 billion in 2022, expected to grow at a compound annual growth rate (CAGR) of 4.5% through 2027.
• Geographical Penetration: North America and Europe account for roughly 70% of the market due to established immunization programs. Asia-Pacific represents the fastest growth, driven by rising vaccination coverage.

Drivers

• Universal Immunization Programs: Governments in developed countries recommend routine vaccination for children, boosting demand.
• Pandemic Disruptions: COVID-19 temporarily slowed vaccination rates, but recovery has been strong, with catch-up campaigns underway.
• Development of Combination Vaccines: Integration of varicella with MMR (measles-mumps-rubella) or other vaccines increases convenience and compliance.

Challenges

• Vaccine Hesitancy: Misinformation impacts uptake in some regions.
• Supply Chain Constraints: Production complexity of live attenuated vaccines requires stringent cold chain logistics.
• Patent and Regulatory Landscape: Competition hinges on patent expirations, regulatory approvals, and manufacturing capacity.

What Are the Market Projections for the Next Five Years?

Forecast Parameters

• Market Growth: Projected to reach USD 3.2 billion by 2027.
• Regional Dynamics: Asia-Pacific, Latin America, and Africa show higher CAGR (6-8%), driven by emerging market expansion.

Key Growth Factors

• Introduction of New Formulations: Nasal and patch-based delivery systems are in early-stage trials, promising to increase compliance.
• Expanded Age Indications: Use in adolescents and adults, especially in regions with low childhood vaccination coverage.
• Increased Immunization Coverage: Global efforts by WHO and GAVI to include varicella in routine immunization schedules.

Competitive Outlook

• Emerging Players: Several biotech firms develop next-generation live attenuated and recombinant varicella vaccines.
• Patent Expiries: Merck’s patent on Varivax expires in 2027, opening market opportunities for biosimilars or generics.
• Regulatory Pathways: Rapid approval pathways, such as WHO prequalification and expanded access programs, facilitate market entry.

What Are the Regulatory and Policy Impacts on the Market?

• Global Approvals: Varivax is approved in over 50 countries; emerging markets often rely on WHO prequalification for procurement.
• Vaccine Policy Adoption: Countries like the US, Germany, and Australia recommend universal childhood varicella vaccination, supporting steady market growth.
• OECD and WHO Regulations: Stringent safety and efficacy standards remain barriers but drive vaccine quality improvements.
• Emerging Markets: Policy shifts encourage inclusion, but affordability remains a challenge.

Key Takeaways

• Clinical development focuses on improving safety, immunogenicity, and expanded use in different populations.
• The existing market is mature but expanding into new regions and formulations.
• Market growth from USD 2.3 billion in 2022 to approximately USD 3.2 billion by 2027.
• Patent expiries and new vaccine formats create opportunities for competitors.
• Regulatory policies are shifting towards broader adoption and simplified approval processes.

FAQs

1. What are the main challenges facing new varicella vaccine developments?

Clinical trials must demonstrate superior safety and efficacy, while manufacturing live vaccines involves complex cold chain logistics. Regulatory hurdles and vaccine hesitancy also pose barriers.

2. How does the market for varicella vaccines compare globally?

North America and Europe dominate the market due to established immunization practices. Asia-Pacific and Latin America are growing segments due to expanding vaccination programs.

3. Will new formulations impact the market?

Yes. Nasal and patch-based vaccines could improve compliance, especially among children and vaccine-hesitant populations, potentially disrupting traditional injectable vaccines.

4. How significant is the impact of patent expirations on the market?

Patent expiries, notably in 2027, will open opportunities for biosimilars and generics, increasing competition and potentially reducing prices.

5. Are there ongoing efforts to expand indications beyond childhood vaccination?

Yes. Trials are assessing use in adolescents, adults, and immunocompromised populations, which could enlarge market size and extend vaccine use cases.

---

Sources

[1] ClinicalTrials.gov, variola virus vaccine live trial registry entries.
[2] Global Market Insights, "Vaccine Market Size," 2022.
[3] WHO, "Guidelines on Varicella Vaccination," 2021.
[4] GAVI, "Coverage and Immunization Campaign Data," 2022.
[5] CDC, "Vaccine Recommendations," 2023.